HRES 484
117th Congress
House
Commerce
Cardiovascular and respiratory health
Competitiveness, trade promotion, trade deficits
Emergency medical services and trauma care
Health technology, devices, supplies
Immunology and vaccination
Infectious and parasitic diseases
Intellectual property
Manufacturing
Expressing the sense of the House of Representatives that the United States should not waive intellectual property rights relating to COVID-19 vaccines or treatments.
Introduced: June 17, 2021
Introduced by:
Miller-Meeks, Mariannette
Republican
· Iowa
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 1, 2022
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Jun 17, 2021
Referred to the House Committee on the Judiciary.
Jun 17, 2021
Introduced in House
Plain-English summary
This resolution expresses the sense of the House of Representatives that the United States should not waive intellectual property protections for COVID-19 vaccines, treatments, or other related innovations.
What's happening now
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Committees of jurisdiction
2